Ventures

RetinaCheck has developed automated diabetic retinopathy screening software that combines brain-inspired geometric methods and CNNs to analyse fundus camera images. It targets the large undetected burden of early diabetic eye damage in China, where roughly 11.6% of the population has type 2 diabetes and retinopathy is the leading cause of new working-age blindness. The software is now widely used across the country.

Nilocas offers a revolutionary solution for detecting coronary artery disease non-invasively and without radiation. Patients wear a lightweight chest patch that captures the sounds of turbulent blood flow through arteries using microphones and accelerometers. Advanced machine learning and AI rapidly analyze the data, providing a clear diagnosis in just 10 minutes. This innovation eliminates the need for costly and invasive procedures, making cardiac diagnosis more accessible in both clinical and non-clinical settings.

The challenge with lung cancer lies in its late detection, often leading to unfortunate outcomes. Current screening methods like low-dose CT scans are costly and have radiation risks, while blood tests lack accuracy or are too expensive. Our solution offers a non-invasive blood test that detects lung cancer early with high sensitivity and specificity. This test, with its multi-protein panel, can identify even stage I cancer, improving survival rates and reducing unnecessary procedures.

MLA Diagnostics improves melanoma diagnosis, offering personalized measurement of malignancy levels. Traditional diagnosis often leads to overtreatment or undertreatment, resulting in patient distress or undetected cancer progression. By analyzing methylation, our test provides accurate prognosis, enabling tailored treatment plans and saving lives. With the melanoma therapeutics market on the rise, our innovative solution is poised to make a significant impact, improve patient outcomes and create opportunities.

ProVascTec offers a novel solution for chronic arterial disease, focusing on peripheral arterial disease (PAD) and chronic limb ischemia. Unlike traditional treatments like angioplasty or bypass surgery, ProVascTec aims to stimulate vascular tissue growth using mesenchymal stem cells, reducing complications and improving blood flow. This innovative approach has the potential to benefit millions of patients suffering from PAD worldwide.

UltraTIL enables real-time tool-in-lesion confirmation during endobronchial lung cancer biopsies. This compact, side-viewing ultrasound probe is designed for the peripheral airways. UltraTil can be inserted through the working channel of a bronchoscope or robotic platform. By visualising lesions perpendicular to the airway and displaying the needle or biopsy instrument entering the target, UltraTIL improves the identification and sampling of small, eccentric and hard-to-reach lesions. The result: higher diagnostic accuracy, less reliance on additional positioning instruments, and shorter, more efficient procedures.

Ansana offers a smart sterilization container for surgical instruments, designed to tackle key challenges in the healthcare sector. By integrating electronic sensors, it ensures sterility in operating rooms, reducing the risk of infections by 10% and lowering the environmental impact of sterilization processes by 85%. Ansana's enhances patient safety with real-time monitoring and traceability features, with complex instruments like endoscopes, while also cutting costs for healthcare facilities in terms of labor and materials.

Altach is tackling the challenge of treating damaged cartilage effectively without costly or complex procedures. Altach's solution is a simple, ready-to-use implant that makes microfracture treatment better. It's made from cartilage-like material and helps the body build new, healthy cartilage. This means fewer surgeries and better outcomes for patients.